Oscar Health Key Executives
This section highlights Oscar Health's key executives, including their titles and compensation details.
Find Contacts at Oscar Health
( total contacts)
Oscar Health Earnings
This section highlights Oscar Health's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-05-07 | $0.83 | $0.92 |
| Read Transcript | Q4 | 2024 | 2025-02-04 | $-0.55 | $-0.62 |
| Read Transcript | Q3 | 2024 | 2024-11-09 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-07 | $0.16 | $0.20 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $0.27 | $0.62 |
| Read Transcript | Q4 | 2023 | 2024-02-07 | $-0.74 | $-0.66 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $-0.47 | $-0.29 |
| Read Transcript | Q2 | 2023 | 2023-08-08 | $-0.33 | $-0.07 |
| Read Transcript | Q1 | 2023 | 2023-05-09 | $-0.05 | $-0.18 |
Financial Statements
Access annual & quarterly financial statements for Oscar Health, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $9.18B | $5.86B | $4.13B | $1.92B | $589.64M |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $9.18B | $5.86B | $4.13B | $1.92B | $589.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $1.76B | $339.72M | $309.78M | $265.08M | $166.66M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.76B | $339.72M | $309.78M | $265.08M | $166.66M |
| Other Expenses | $7.36B | $5.76B | $4.24B | $-2.76B | $-1.16B |
| Operating Expenses | $9.12B | $6.10B | $4.55B | $-2.50B | $-996.50M |
| Cost and Expenses | $9.12B | $6.10B | $4.74B | $2.49B | $995.42M |
| Interest Income | $- | $- | $31.31M | $10.25M | $8.01M |
| Interest Expense | $23.73M | $24.60M | $22.62M | $4.72M | $3.51M |
| Depreciation and Amortization | $32.15M | $30.69M | $15.28M | $14.61M | $11.30M |
| EBITDA | $88.62M | $-212.00M | $-572.17M | $-551.25M | $-390.97M |
| EBITDA Ratio | 0.97% | -3.62% | -13.87% | -28.70% | -66.31% |
| Operating Income | $57.27M | $-235.62M | $-584.17M | $-577.06M | $-406.86M |
| Operating Income Ratio | 0.62% | -4.02% | -14.16% | -30.04% | -69.00% |
| Total Other Income Expenses Net | $-23.84M | $-31.68M | $-20.21M | $-26.10M | $-3.51M |
| Income Before Tax | $33.43M | $-267.30M | $-610.08M | $-570.58M | $-405.78M |
| Income Before Tax Ratio | 0.36% | -4.56% | -14.79% | -29.70% | -68.82% |
| Income Tax Expense | $7.30M | $3.29M | $-523.00K | $846.00K | $1.04M |
| Net Income | $25.43M | $-270.73M | $-609.55M | $-571.43M | $-406.82M |
| Net Income Ratio | 0.28% | -4.62% | -14.77% | -29.75% | -69.00% |
| EPS | $0.11 | $-1.22 | $-2.87 | $-3.19 | $-1.70 |
| EPS Diluted | $0.10 | $-1.22 | $-2.87 | $-3.19 | $-1.70 |
| Weighted Average Shares Outstanding | 240.39M | 221.66M | 212.47M | 178.97M | 239.31M |
| Weighted Average Shares Outstanding Diluted | 265.85M | 221.66M | 212.47M | 178.97M | 239.31M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.05B | $2.39B | $2.42B | $2.22B | $2.14B | $1.43B | $1.44B | $1.52B | $1.47B | $1.04B | $40.09M | $1.06B | $1.01B | $520.33M | $462.19M | $549.75M | $369.39M | $187.63M | $133.31M | $145.57M |
| Cost of Revenue | $- | $1 | $- | $- | $- | $976.00K | $-30.00K | $589.00K | $- | $- | $- | $- | $- | $- | $- | $- | $-19.31M | $- | $- | $- |
| Gross Profit | $3.05B | $2.39B | $2.42B | $2.22B | $2.14B | $1.43B | $1.44B | $1.52B | $1.47B | $1.04B | $40.09M | $1.06B | $1.01B | $520.33M | $462.19M | $549.75M | $388.69M | $187.63M | $133.31M | $145.57M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.93% | 100.00% | 99.96% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 105.23% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $482.76M | $466.58M | $459.52M | $435.14M | $394.70M | $85.61M | $75.50M | $76.45M | $396.98M | $75.81M | $78.56M | $80.75M | $74.66M | $89.34M | $61.27M | $50.91M | $63.06M | $62.28M | $36.55M | $35.99M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $482.76M | $466.58M | $459.52M | $435.14M | $394.70M | $85.61M | $75.50M | $76.45M | $396.98M | $75.81M | $78.56M | $80.75M | $74.66M | $89.34M | $61.27M | $50.91M | $63.06M | $62.28M | $36.55M | $35.99M |
| Other Expenses | $2.28B | $2.07B | $2.01B | $-442.81M | $-401.97M | $1.49B | $1.42B | $1.45B | $1.07B | $2.18B | $1.09B | $-149.50M | $-1.16B | $602.98M | $595.66M | $550.62M | $368.86M | $-436.74M | $-249.99M | $-220.92M |
| Operating Expenses | $2.76B | $2.54B | $2.47B | $442.81M | $401.97M | $1.58B | $1.50B | $1.53B | $1.47B | $2.26B | $1.17B | $1.13B | $-1.08B | $692.32M | $656.92M | $601.53M | $431.92M | $-374.47M | $-213.44M | $-184.93M |
| Cost and Expenses | $2.76B | $2.54B | $2.47B | $-2.15B | $-1.96B | $1.58B | $1.50B | $1.54B | $1.47B | $1.26B | $1.21B | $1.17B | $1.09B | $718.18M | $675.53M | $622.23M | $455.79M | $377.98M | $213.44M | $184.93M |
| Interest Income | $- | $- | $- | $- | $- | $- | $6.13M | $6.12M | $- | $6.13M | $6.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $5.99M | $6.03M | $5.82M | $5.99M | $5.90M | $6.22M | $6.13M | $6.12M | $6.14M | $6.13M | $6.13M | $6.14M | $4.22M | $397.00K | $398.00K | $228.00K | $3.70M | $3.51M | $- | $- |
| Depreciation and Amortization | $6.73M | $9.23M | $7.50M | $7.60M | $7.81M | $7.74M | $9.19M | $8.82M | $4.94M | $3.73M | $4.06M | $3.69M | $3.80M | $3.97M | $3.65M | $3.59M | $3.40M | $3.29M | $2.92M | $2.52M |
| EBITDA | $300.94M | $-138.69M | $-39.20M | $74.54M | $192.19M | $-136.69M | $-49.47M | $681.00K | $-26.53M | $-217.41M | $-184.98M | $-102.00M | $-67.78M | $-193.49M | $-209.30M | $-68.66M | $-79.31M | $-183.53M | $-77.20M | $-36.83M |
| EBITDA Ratio | 9.88% | -5.80% | -1.62% | 3.36% | 8.97% | -9.55% | -3.44% | 0.04% | -1.81% | -20.95% | -461.45% | -9.64% | -6.70% | -37.19% | -45.28% | -12.49% | -21.47% | -97.81% | -57.91% | -25.30% |
| Operating Income | $288.21M | $-147.73M | $-48.37M | $67.81M | $185.56M | $-145.48M | $-58.24M | $-6.53M | $- | $-220.63M | $-185.17M | $-106.49M | $-69.41M | $-198.64M | $-212.94M | $-72.25M | $-62.53M | $-186.84M | $-80.13M | $-39.35M |
| Operating Income Ratio | 9.46% | -6.17% | -2.00% | 3.06% | 8.66% | -10.16% | -4.04% | -0.43% | 0.00% | -21.26% | -461.94% | -10.06% | -6.87% | -38.18% | -46.07% | -13.14% | -16.93% | -99.58% | -60.11% | -27.03% |
| Total Other Income Expenses Net | $- | $-5.96M | $-3.94M | $-6.86M | $-7.08M | $-5.17M | $-6.54M | $-7.73M | $-37.61M | $-4.80M | $-2.79M | $-5.35M | $-7.27M | $-1.60M | $-398.00K | $-228.00K | $-23.88M | $-3.51M | $- | $- |
| Income Before Tax | $288.21M | $-153.69M | $-52.31M | $60.95M | $178.48M | $-150.64M | $-64.79M | $-14.26M | $-37.61M | $-227.28M | $-195.16M | $-111.83M | $-75.80M | $-197.85M | $-213.34M | $-72.48M | $-86.41M | $-190.35M | $-80.13M | $-39.35M |
| Income Before Tax Ratio | 9.46% | -6.42% | -2.16% | 2.75% | 8.33% | -10.52% | -4.50% | -0.94% | -2.56% | -21.90% | -486.86% | -10.57% | -7.50% | -38.02% | -46.16% | -13.18% | -23.39% | -101.45% | -60.11% | -27.03% |
| Income Tax Expense | $12.71M | $-404.00K | $2.08M | $4.64M | $996.00K | $-806.00K | $915.00K | $1.16M | $2.02M | $-715.00K | $-1.61M | $290.00K | $1.52M | $-111.00K | $-597.00K | $589.00K | $965.00K | $-481.00K | $-998.00K | $1.59M |
| Net Income | $275.27M | $-153.55M | $-54.60M | $56.21M | $177.37M | $-150.03M | $-65.40M | $-15.53M | $-39.77M | $-226.56M | $-193.55M | $-112.16M | $-77.32M | $-198.92M | $-212.75M | $-73.07M | $-87.37M | $-189.87M | $-79.13M | $-40.94M |
| Net Income Ratio | 9.04% | -6.42% | -2.25% | 2.53% | 8.28% | -10.48% | -4.54% | -1.02% | -2.71% | -21.83% | -482.83% | -10.60% | -7.65% | -38.23% | -46.03% | -13.29% | -23.65% | -101.19% | -59.36% | -28.13% |
| EPS | $1.10 | $-0.62 | $-0.22 | $0.24 | $0.77 | $-0.66 | $-0.29 | $-0.07 | $-0.18 | $-1.05 | $-0.91 | $-0.53 | $-0.37 | $-0.95 | $-1.02 | $-0.35 | $-0.98 | $-0.96 | $-2.70 | $-1.40 |
| EPS Diluted | $0.92 | $-0.62 | $-0.22 | $0.18 | $0.60 | $-0.66 | $-0.29 | $-0.07 | $-0.18 | $-1.05 | $-0.91 | $-0.53 | $-0.37 | $-0.95 | $-1.02 | $-0.35 | $-0.98 | $-0.93 | $-0.39 | $-0.20 |
| Weighted Average Shares Outstanding | 251.28M | 240.39M | 243.11M | 238.67M | 231.44M | 227.08M | 223.10M | 219.40M | 216.91M | 215.19M | 212.82M | 211.31M | 210.55M | 209.78M | 208.16M | 207.48M | 88.87M | 197.08M | 29.26M | 29.26M |
| Weighted Average Shares Outstanding Diluted | 305.94M | 265.85M | 243.11M | 303.96M | 293.80M | 227.08M | 223.10M | 219.40M | 216.91M | 215.19M | 212.82M | 211.31M | 210.55M | 209.78M | 208.16M | 207.48M | 88.87M | 203.14M | 203.14M | 203.14M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.53B | $1.87B | $1.56B | $1.10B | $826.33M |
| Short Term Investments | $624.46M | $689.83M | $1.40B | $587.09M | $366.39M |
| Cash and Short Term Investments | $2.15B | $2.56B | $2.96B | $1.69B | $1.19B |
| Net Receivables | $315.89M | $201.27M | $- | $179.07M | $96.48M |
| Inventory | $- | $- | $-1.16B | $-614.85M | $-1.29B |
| Other Current Assets | $377.64M | $- | $1.17B | $- | $- |
| Total Current Assets | $2.85B | $2.82B | $4.12B | $1.87B | $1.29B |
| Property Plant Equipment Net | $66.79M | $61.93M | $59.89M | $46.61M | $35.81M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $633.10M | $398.80M |
| Long Term Investments | $1.82B | $365.31M | $1.40B | $587.09M | $366.39M |
| Tax Assets | $- | $- | $- | $595.00K | $3.40M |
| Other Non-Current Assets | $113.28M | $113.14M | $-1.05B | $-633.70M | $-402.20M |
| Total Non-Current Assets | $2.00B | $540.38M | $405.05M | $633.70M | $402.20M |
| Other Assets | $- | $241.19M | $- | $817.80M | $580.72M |
| Total Assets | $4.84B | $3.60B | $4.53B | $3.32B | $2.27B |
| Account Payables | $1.40B | $334.39M | $1.37B | $440.02M | $480.84M |
| Short Term Debt | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.77B | $2.09B | $1.90B | $-440.02M | $-480.84M |
| Total Current Liabilities | $3.17B | $2.43B | $3.26B | $440.02M | $480.84M |
| Long Term Debt | $299.56M | $298.78M | $298.00M | $- | $142.49M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $139.59M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $4.11M | $2.90M |
| Other Non-Current Liabilities | $61.28M | $67.57M | $72.28M | $1.93B | $-142.49M |
| Total Non-Current Liabilities | $360.84M | $366.35M | $370.28M | $76.84M | $142.49M |
| Other Liabilities | $291.54M | $- | $- | $-76.84M | $2.94B |
| Total Liabilities | $3.82B | $2.80B | $3.63B | $440.02M | $3.57B |
| Preferred Stock | $- | $- | $- | $3.32B | $1.74B |
| Common Stock | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K |
| Retained Earnings | $-2.85B | $-2.88B | $-2.61B | $-2.00B | $-1.43B |
| Accumulated Other Comprehensive Income Loss | $-1.83M | $1.31M | $-9.71M | $-3.67M | $879.00K |
| Other Total Stockholders Equity | $3.87B | $3.68B | $3.51B | $3.39B | $-1.61B |
| Total Stockholders Equity | $1.01B | $803.97M | $890.38M | $1.39B | $-1.30B |
| Total Equity | $1.02B | $806.12M | $892.40M | $1.39B | $-1.30B |
| Total Liabilities and Stockholders Equity | $4.84B | $3.60B | $4.53B | $3.32B | $2.27B |
| Minority Interest | $2.84M | $2.15M | $2.02M | $5.29M | $- |
| Total Liabilities and Total Equity | $4.84B | $3.60B | $4.53B | $3.32B | $2.27B |
| Total Investments | $2.44B | $1.06B | $1.62B | $1.43B | $692.13M |
| Total Debt | $299.56M | $298.78M | $298.00M | $- | $142.49M |
| Net Debt | $-1.23B | $-1.57B | $-1.26B | $-1.10B | $-683.84M |
Balance Sheet Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.24B | $1.53B | $1.21B | $2.27B | $2.23B | $1.87B | $1.40B | $2.32B | $2.11B | $1.56B | $2.11B | $2.36B | $2.07B | $1.10B | $1.08B | $1.67B | $2.32B | $826.33M | $- |
| Short Term Investments | $751.49M | $624.46M | $503.78M | $363.64M | $616.13M | $689.83M | $1.04B | $1.26B | $1.32B | $1.40B | $718.23M | $909.01M | $810.00M | $587.09M | $586.95M | $614.98M | $389.02M | $366.39M | $- |
| Cash and Short Term Investments | $2.99B | $2.15B | $1.71B | $2.63B | $2.85B | $2.56B | $2.44B | $3.58B | $3.43B | $2.96B | $2.83B | $3.27B | $2.88B | $1.69B | $1.66B | $2.29B | $2.71B | $1.19B | $- |
| Net Receivables | $763.44M | $315.89M | $300.63M | $711.79M | $647.88M | $494.39M | $207.10M | $193.08M | $686.39M | $- | $215.47M | $968.97M | $157.30M | $- | $- | $- | $- | $96.48M | $- |
| Inventory | $- | $- | $- | $-2.67B | $-656.86M | $-3.05B | $-331.93M | $-414.22M | $- | $-1.16B | $-868.73M | $-5.40B | $-638.89M | $- | $-160.63M | $-125.55M | $- | $- | $- |
| Other Current Assets | $297.69M | $377.64M | $357.49M | $- | $- | $- | $340.29M | $421.78M | $-4.12B | $1.17B | $884.54M | $- | $- | $614.85M | $577.51M | $529.51M | $469.06M | $- | $- |
| Total Current Assets | $- | $2.85B | $2.37B | $3.12B | $3.26B | $2.82B | $2.99B | $4.19B | $5.64B | $4.12B | $3.93B | $2.36B | $3.09B | $2.31B | $2.24B | $2.82B | $3.18B | $1.29B | $- |
| Property Plant Equipment Net | $72.00M | $66.79M | $66.63M | $63.95M | $61.41M | $61.93M | $62.02M | $63.05M | $64.08M | $59.89M | $56.49M | $50.93M | $48.61M | $46.61M | $43.38M | $40.87M | $38.99M | $35.81M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $858.01M | $- | $251.32M | $188.31M | $-485.00K | $- | $- |
| Long Term Investments | $1.87B | $1.82B | $1.93B | $363.64M | $616.13M | $29.87M | $1.04B | $1.26B | $165.24M | $1.40B | $718.23M | $909.01M | $810.00M | $587.09M | $586.95M | $614.98M | $389.02M | $366.39M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $595.00K | $595.00K | $485.00K | $467.00K | $485.00K | $- | $- |
| Other Non-Current Assets | $124.59M | $113.28M | $114.44M | $1.22B | $237.52M | $448.58M | $-748.58M | $-946.45M | $-229.32M | $-1.05B | $-397.19M | $1.43B | $-858.61M | $381.43M | $46.59M | $45.82M | $-389.02M | $-402.20M | $- |
| Total Non-Current Assets | $2.07B | $2.00B | $2.11B | $1.65B | $915.06M | $540.38M | $357.89M | $372.31M | $-1.16B | $405.05M | $377.54M | $2.39B | $858.61M | $1.02B | $928.72M | $890.45M | $38.99M | $402.20M | $- |
| Other Assets | $5.84B | $- | $- | $- | $- | $- | $- | $- | $4.48B | $- | $- | $- | $405.37M | $- | $- | $- | $376.00M | $580.72M | $- |
| Total Assets | $5.84B | $4.84B | $4.48B | $4.76B | $4.18B | $3.36B | $3.35B | $4.56B | $4.48B | $4.53B | $4.31B | $4.75B | $4.35B | $3.32B | $3.17B | $3.71B | $3.59B | $2.27B | $- |
| Account Payables | $1.49B | $1.40B | $1.41B | $407.62M | $365.18M | $334.39M | $977.76M | $923.35M | $994.53M | $1.37B | $1.43B | $657.19M | $612.75M | $718.81M | $718.63M | $655.46M | $618.12M | $480.84M | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $2.66B | $2.07B | $-1.41B | $2.85B | $2.41B | $-334.39M | $-977.76M | $2.32B | $-994.53M | $1.90B | $-1.43B | $-657.19M | $-612.75M | $-718.81M | $-718.63M | $-655.46M | $-618.12M | $-480.84M | $- |
| Total Current Liabilities | $4.15B | $3.46B | $5.45B | $3.26B | $2.78B | $2.19B | $2.06B | $3.24B | $- | $3.26B | $2.85B | $657.19M | $612.75M | $1.85B | $1.62B | $1.97B | $1.81B | $480.84M | $- |
| Long Term Debt | $299.75M | $299.56M | $299.36M | $299.17M | $298.97M | $298.78M | $298.58M | $298.39M | $298.19M | $298.00M | $297.81M | $297.61M | $297.42M | $- | $- | $- | $- | $142.49M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.11M | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $59.33M | $61.28M | $63.54M | $64.67M | $66.17M | $2.50B | $68.62M | $70.28M | $-298.19M | $72.28M | $73.79M | $3.21B | $2.72B | $1.93B | $- | $- | $- | $-142.49M | $- |
| Total Non-Current Liabilities | $359.08M | $360.84M | $362.90M | $363.84M | $365.14M | $366.35M | $367.20M | $368.66M | $- | $370.28M | $371.60M | $297.61M | $297.42M | $76.84M | $1.49B | $1.83B | $1.66B | $142.49M | $- |
| Other Liabilities | $4.51B | $- | $-2.49B | $- | $- | $- | $- | $- | $3.55B | $- | $- | $2.55B | $2.11B | $- | $-1.49B | $-1.83B | $-1.66B | $2.94B | $- |
| Total Liabilities | $4.51B | $3.82B | $3.32B | $3.62B | $3.14B | $2.55B | $2.43B | $3.61B | $3.55B | $3.63B | $3.22B | $3.50B | $3.02B | $1.93B | $1.62B | $1.97B | $1.81B | $3.57B | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.17B | $3.71B | $3.59B | $1.74B | $1.30B |
| Common Stock | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $- |
| Retained Earnings | $-2.58B | $-2.85B | $-2.70B | $-2.64B | $-2.70B | $-2.88B | $-2.73B | $-2.66B | $-2.65B | $-2.61B | $-2.38B | $-2.19B | $-2.07B | $-2.00B | $-1.80B | $-1.59B | $-1.51B | $-1.43B | $- |
| Accumulated Other Comprehensive Income Loss | $9.60M | $-1.83M | $26.05M | $-2.62M | $-2.59M | $1.31M | $-4.45M | $-6.86M | $-4.48M | $-9.71M | $-14.49M | $-15.22M | $-12.21M | $-3.67M | $17.00K | $-40.00K | $604.00K | $879.00K | $-945.14M |
| Other Total Stockholders Equity | $3.90B | $3.87B | $3.83B | $3.78B | $3.73B | $3.68B | $3.65B | $3.62B | $3.58B | $3.51B | $3.48B | $3.45B | $3.42B | $3.39B | $3.35B | $3.32B | $3.30B | $-1.61B | $- |
| Total Stockholders Equity | $1.33B | $1.01B | $1.16B | $1.14B | $1.03B | $803.97M | $919.48M | $949.70M | $929.60M | $890.38M | $1.08B | $1.25B | $1.33B | $1.39B | $1.55B | $1.73B | $1.79B | $-1.30B | $350.61M |
| Total Equity | $1.34B | $1.02B | $1.17B | $1.14B | $1.03B | $806.12M | $921.43M | $951.97M | $931.76M | $892.40M | $1.08B | $1.25B | $1.34B | $1.39B | $1.55B | $1.73B | $1.79B | $-1.30B | $350.61M |
| Total Liabilities and Stockholders Equity | $5.84B | $4.84B | $4.48B | $4.76B | $4.18B | $3.36B | $3.35B | $4.56B | $4.48B | $4.53B | $4.31B | $4.75B | $4.35B | $3.32B | $3.17B | $3.71B | $3.59B | $2.27B | $350.61M |
| Minority Interest | $3.07M | $2.84M | $2.58M | $2.37M | $2.26M | $2.15M | $1.96M | $2.26M | $2.16M | $2.02M | $2.53M | $3.16M | $3.12M | $5.29M | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.84B | $4.84B | $4.48B | $4.76B | $4.18B | $3.36B | $3.35B | $4.56B | $4.48B | $4.53B | $4.31B | $4.75B | $4.35B | $3.32B | $3.17B | $3.71B | $3.59B | $2.27B | $350.61M |
| Total Investments | $2.62B | $2.44B | $2.44B | $363.64M | $616.13M | $719.70M | $1.22B | $1.45B | $1.49B | $1.62B | $914.68M | $1.22B | $1.31B | $1.43B | $1.43B | $1.42B | $718.61M | $692.13M | $- |
| Total Debt | $299.75M | $299.56M | $299.36M | $299.17M | $298.97M | $298.78M | $298.58M | $298.39M | $298.19M | $298.00M | $297.81M | $297.61M | $297.42M | $- | $- | $- | $- | $142.49M | $- |
| Net Debt | $-1.94B | $-1.23B | $-906.78M | $-1.97B | $-1.93B | $-1.57B | $-1.10B | $-2.02B | $-1.81B | $-1.26B | $-1.82B | $-2.07B | $-1.77B | $-1.10B | $-1.08B | $-1.67B | $-2.32B | $-683.84M | $- |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $26.12M | $-270.73M | $-609.55M | $-571.43M | $-406.82M |
| Depreciation and Amortization | $32.15M | $30.69M | $15.28M | $14.61M | $11.29M |
| Deferred Income Tax | $-2.34M | $58.00K | $-165.00K | $-101.00K | $-67.00K |
| Stock Based Compensation | $109.82M | $159.68M | $112.33M | $86.30M | $35.87M |
| Change in Working Capital | $838.86M | $-192.09M | $857.99M | $247.70M | $575.70M |
| Accounts Receivables | $- | $636.23M | $-538.96M | $80.45M | $-98.58M |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $152.77M | $-395.81M | $280.23M | $-39.46M | $-13.40M |
| Other Working Capital | $686.10M | $-432.50M | $1.12B | $206.71M | $687.68M |
| Other Non Cash Items | $-26.42M | $220.00K | $4.47M | $41.19M | $6.77M |
| Net Cash Provided by Operating Activities | $978.19M | $-272.16M | $380.35M | $-181.75M | $222.73M |
| Investments in Property Plant and Equipment | $-27.90M | $-25.58M | $-29.01M | $-25.89M | $-14.02M |
| Acquisitions Net | $- | $- | $- | $7.23M | $- |
| Purchases of Investments | $-2.13B | $-839.26M | $-1.19B | $-1.81B | $-1.00B |
| Sales Maturities of Investments | $770.04M | $1.44B | $994.08M | $1.05B | $671.59M |
| Other Investing Activities | $3.93M | $- | $1.12M | $-555.00K | $-1.24M |
| Net Cash Used for Investing Activities | $-1.39B | $577.19M | $-226.52M | $-774.51M | $-344.71M |
| Debt Repayment | $- | $- | $305.00M | $-153.17M | $147.00M |
| Common Stock Issued | $- | $- | $1.30M | $1.35B | $469.55M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $68.39M | $6.45M | $-3.89M | $43.56M | $464.71M |
| Net Cash Used Provided by Financing Activities | $68.39M | $6.45M | $301.11M | $1.24B | $611.71M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-340.85M | $311.47M | $454.94M | $282.45M | $489.73M |
| Cash at End of Period | $1.55B | $1.89B | $1.58B | $1.13B | $843.11M |
| Cash at Beginning of Period | $1.89B | $1.58B | $1.13B | $843.11M | $353.38M |
| Operating Cash Flow | $978.19M | $-272.16M | $380.35M | $-181.75M | $222.73M |
| Capital Expenditure | $-27.90M | $-25.58M | $-29.01M | $-25.89M | $-14.02M |
| Free Cash Flow | $950.30M | $-297.74M | $351.34M | $-207.63M | $208.71M |
Cash Flow Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $275.51M | $-153.55M | $-54.17M | $56.21M | $177.37M | $-150.03M | $-65.70M | $-15.43M | $-39.77M | $-226.56M | $-193.55M | $-112.12M | $-77.32M | $-198.24M | $-212.75M | $-73.07M | $-87.37M | $-189.87M | $-79.13M | $-40.94M |
| Depreciation and Amortization | $6.73M | $9.23M | $7.50M | $7.60M | $7.81M | $7.74M | $9.19M | $8.82M | $4.94M | $3.73M | $4.06M | $3.69M | $3.80M | $3.97M | $3.65M | $3.59M | $3.40M | $3.29M | $2.92M | $2.52M |
| Deferred Income Tax | $36.00K | $-2.27M | $-119.00K | $130.00K | $-79.00K | $-37.00K | $69.00K | $209.00K | $-183.00K | $-171.00K | $2.00K | $4.00K | $- | $-109.00K | $-18.00K | $18.00K | $8.00K | $-67.00K | $-125.00K | $5.00K |
| Stock Based Compensation | $24.98M | $25.86M | $29.31M | $28.71M | $25.95M | $26.14M | $28.77M | $33.28M | $71.49M | $29.09M | $28.56M | $26.99M | $27.69M | $28.27M | $20.64M | $18.27M | $19.11M | $13.88M | $7.29M | $6.60M |
| Change in Working Capital | $587.54M | $473.84M | $-840.63M | $410.39M | $430.24M | $390.57M | $-1.11B | $146.43M | $376.69M | $346.76M | $-389.39M | $294.57M | $606.05M | $197.99M | $-403.21M | $104.71M | $348.21M | $255.04M | $-149.37M | $276.21M |
| Accounts Receivables | $- | $97.87M | $98.12M | $-53.61M | $-142.38M | $13.83M | $62.06M | $91.31M | $464.34M | $-69.41M | $-125.50M | $-171.47M | $-172.58M | $-32.94M | $-45.52M | $-55.96M | $214.87M | $66.74M | $-222.87M | $225.71M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $18.20M | $- | $- | $-1.14B | $- | $-1.43B | $- |
| Accounts Payables | $199.63M | $24.92M | $47.76M | $40.94M | $29.39M | $5.89M | $-3.36M | $-11.87M | $-386.48M | $35.99M | $29.68M | $42.29M | $172.27M | $57.25M | $-2.75M | $2.51M | $-96.48M | $-148.59M | $128.83M | $-128.98M |
| Other Working Capital | $488.20M | $473.84M | $-986.50M | $423.07M | $542.77M | $370.85M | $-1.17B | $66.99M | $298.82M | $380.19M | $-293.57M | $309.92M | $606.36M | $155.48M | $-354.95M | $158.15M | $1.37B | $336.88M | $1.37B | $179.48M |
| Other Non Cash Items | $- | $-6.29M | $357.96M | $-5.89M | $34.57M | $22.48M | $-7.33M | $-7.79M | $1.55M | $-1.46M | $1.95M | $1.22M | $2.63M | $2.60M | $2.44M | $1.82M | $34.32M | $6.70M | $-506.00K | $1.93M |
| Net Cash Provided by Operating Activities | $878.54M | $346.82M | $-500.14M | $497.15M | $634.36M | $296.87M | $-1.15B | $165.52M | $414.71M | $151.39M | $-548.36M | $214.47M | $562.85M | $34.48M | $-589.25M | $55.34M | $317.69M | $88.98M | $-218.92M | $246.32M |
| Investments in Property Plant and Equipment | $-9.03M | $-6.82M | $-7.57M | $-7.56M | $-5.95M | $-6.10M | $-6.48M | $-5.62M | $-7.38M | $-7.13M | $-9.62M | $-6.02M | $-6.25M | $-7.21M | $-6.15M | $-5.95M | $-6.58M | $-3.33M | $-2.83M | $-3.89M |
| Acquisitions Net | $- | $- | $- | $- | $- | $2.38M | $- | $- | $- | $- | $- | $- | $- | $7.23M | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-336.87M | $-110.46M | $-660.06M | $-806.30M | $-556.69M | $-217.08M | $-84.50M | $-335.04M | $-202.65M | $-849.53M | $-31.07M | $-145.34M | $-166.77M | $-284.17M | $-327.58M | $-952.63M | $-245.69M | $-162.11M | $-671.19M | $-16.99M |
| Sales Maturities of Investments | $171.67M | $85.84M | $87.36M | $334.78M | $262.05M | $395.65M | $315.65M | $385.07M | $345.54M | $150.41M | $338.94M | $229.52M | $275.22M | $268.49M | $317.74M | $250.54M | $218.00M | $180.59M | $240.59M | $47.30M |
| Other Investing Activities | $- | $-13.00K | $2.49M | $1.45M | $626.00K | $-2.38M | $622.00K | $-522.00K | $- | $-432.00K | $525.00K | $412.00K | $611.00K | $3.05M | $3.62M | $-702.09M | $-27.70M | $-520.00K | $287.00K | $-654.00K |
| Net Cash Used for Investing Activities | $-174.23M | $-31.45M | $-577.77M | $-477.63M | $-300.59M | $172.48M | $225.30M | $43.90M | $135.51M | $-706.68M | $298.77M | $78.58M | $102.81M | $-19.84M | $-12.36M | $-708.03M | $-34.28M | $14.64M | $-433.14M | $25.77M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $305.00M | $- | $- | $- | $-153.17M | $- | $- | $- |
| Common Stock Issued | $- | $- | $-46.01M | $- | $27.31M | $1.07M | $300.00K | $2.55M | $- | $1.30M | $370.00K | $364.00K | $560.00K | $5.74M | $11.20M | $2.99M | $1.35B | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.87M | $3.82M | $18.56M | $- | $27.31M | $1.07M | $2.32M | $2.55M | $506.00K | $527.00K | $423.00K | $1.39M | $-6.22M | $12.97M | $11.20M | $2.99M | $16.40M | $385.27M | $1.24M | $224.75M |
| Net Cash Used Provided by Financing Activities | $4.87M | $3.82M | $18.56M | $18.70M | $27.31M | $1.07M | $2.32M | $2.55M | $506.00K | $527.00K | $423.00K | $1.39M | $298.77M | $12.97M | $11.20M | $2.99M | $1.21B | $385.27M | $1.24M | $224.75M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $-504.30M | $960.52M | $-254.07M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $709.19M | $319.19M | $-1.06B | $37.35M | $360.48M | $470.52M | $-921.64M | $211.97M | $550.73M | $-554.76M | $-249.16M | $294.43M | $964.43M | $27.61M | $-590.41M | $-649.71M | $1.49B | $488.89M | $-650.83M | $496.85M |
| Cash at End of Period | $2.26B | $1.55B | $1.23B | $2.27B | $2.23B | $1.87B | $1.42B | $2.34B | $2.13B | $1.58B | $2.14B | $2.38B | $2.09B | $1.13B | $1.10B | $1.69B | $2.34B | $843.11M | $354.21M | $1.01B |
| Cash at Beginning of Period | $1.55B | $1.23B | $2.29B | $2.23B | $1.87B | $1.40B | $2.34B | $2.13B | $1.58B | $2.14B | $2.38B | $2.09B | $1.13B | $1.10B | $1.69B | $2.34B | $843.11M | $354.21M | $1.01B | $508.18M |
| Operating Cash Flow | $878.54M | $346.82M | $-500.14M | $497.15M | $634.36M | $296.87M | $-1.15B | $165.52M | $414.71M | $151.39M | $-548.36M | $214.47M | $562.85M | $34.48M | $-589.25M | $55.34M | $317.69M | $88.98M | $-218.92M | $246.32M |
| Capital Expenditure | $-9.03M | $-6.82M | $-7.57M | $-7.56M | $-5.95M | $-6.10M | $-6.48M | $-5.62M | $-7.38M | $-7.13M | $-9.62M | $-6.02M | $-6.25M | $-7.21M | $-6.15M | $-5.95M | $-6.58M | $-3.33M | $-2.83M | $-3.89M |
| Free Cash Flow | $869.52M | $340.00M | $-507.71M | $489.59M | $628.41M | $290.77M | $-1.16B | $159.91M | $407.34M | $144.26M | $-557.98M | $208.45M | $556.60M | $27.27M | $-595.40M | $49.39M | $311.11M | $85.66M | $-221.75M | $242.43M |
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
$16.90
Stock Price
$3.70B
Market Cap
2.40K
Employees
New York, NY
Location
Revenue (FY 2024)
$9.18B
56.5% YoY
Net Income (FY 2024)
$25.43M
109.4% YoY
EPS (FY 2024)
$0.10
107.8% YoY
Free Cash Flow (FY 2024)
$950.30M
419.2% YoY
Profitability
Gross Margin
100.0%
Net Margin
0.3%
ROE
2.5%
ROA
0.5%
Valuation
P/E Ratio
127.04
P/S Ratio
0.35
EV/EBITDA
22.60
Market Cap
$3.70B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$978.19M
459.4% YoY
Free Cash Flow
$950.30M
419.2% YoY
Balance Sheet Summary
Total Assets
$4.84B
34.4% YoY
Total Debt
$299.56M
0.3% YoY
Shareholder Equity
$1.01B
16.3% YoY
Dividend Overview
No Dividend Data
Oscar Health, Inc. doesn't currently pay dividends.
Oscar Health Dividends
Explore Oscar Health's dividend history, including dividend yield, payout ratio, and historical payments.
Oscar Health News
Read the latest news about Oscar Health, including recent articles, headlines, and updates.
Oscar Health: Steep Budget Cuts In 2026 Healthcare Estimates Spell Uncertainty
I rate Oscar Health as a Hold, due to proposed steep budget cuts in the 2026 budget, impacting Medicaid and Medicare Advantage coverage. Oscar Health's impressive financials and revenue growth are overshadowed by macroeconomic risks, including potential policy changes and increased uninsured rates. Despite strong internal operations and a projected revenue CAGR of ~20% between 2024 and 2027, external factors pose significant risks to growth.
Oscar Health: The Healthcare Disruptor Just Hit Its Stride
Oscar Health, Inc. delivered strong Q1 results with 42% revenue growth, improved cost control, and expanding membership, signaling sustainable profitability and margin expansion. The company stands to benefit from competitor exits in ACA exchanges and potential policy changes lowering prescription drug costs, enhancing long-term operating leverage. Despite a high current P/E, forward multiples and consensus EPS growth suggest Oscar is undervalued with >41% upside potential in the next 12-18 months.
Oscar Health, Inc. (OSCR) Q1 2025 Earnings Call Transcript
Oscar Health, Inc. (NYSE:OSCR ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury and Investor Relations Mark Bertolini - Chief Executive Officer Scott Blackley - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Stephen Baxter - Wells Fargo Jonathan Yong - UBS Joanna Gajuk - Bank of America Josh Raskin - Nephron Research Jessica Tassan - Piper Sandler Michael Ha - Baird David Windley - Jefferies Operator Good morning, everyone. My name is Ellie, and I will be your conference operator for today.
Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. “Oscar reported strong financial results in the first quarter,” said Mark Bertolini, CEO of Oscar Health. “We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expans.
Here's how Oscar Health CEO Mark Bertolini wants to fix the health insurance system
Mark Bertolini, Oscar Health CEO and former Aetna chairman and CEO, discusses potential solutions to some of the problems in the health insurance industry and why he believes the individual insurance market is the solution for Americans.
Oscar Health CEO on fixing the health insurance system: Individual insurance market is the solution
Mark Bertolini, Oscar Health CEO and former Aetna chairman and CEO, joins 'Squawk Box' to discuss potential solutions to some of the problems in the health insurance industry, why he believes the individual insurance market is the solution for Americans, and more.
Oscar Health: The Most Undervalued Small Cap But With One Big Risk
I am bullish on Oscar Health (OSCR) due to its efficient D2C model, AI integration, and improving EBITDA margins despite high revenue growth. OSCR's opportunity in the ICHRA market is significant, with projections to increase 3x-5x by 2030, positioning it well against larger competitors. Risks include potential changes to ACA subsidies under future administrations, which could disrupt OSCR's current business model and force a shift to ICHRA.
Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus,.
Oscar Health, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - OSCR
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Oscar Health, Inc. (OSCR) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
ATTENTION Oscar Health, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
OSCR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Oscar Health, Inc.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Oscar Health, Inc. Being Investigated on Behalf of Oscar Health, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Shareholders that lost money on Oscar Health, Inc.(OSCR) should contact Levi & Korsinsky about Securities Fraud Investigation - OSCR
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Lost Money on Oscar Health, Inc. (OSCR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Shareholders That Lost Money on Oscar Health, Inc. (OSCR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - OSCR
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Oscar Health, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- OSCR
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Oscar Health, Inc. (OSCR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for OSCR.